[PERSON]
Wegovy
Featured in 2 tracked stories · first seen
Situations
GLP-1 obesity drug rollout and market expansion
105 clusters · 510 sources · last updated
Latest: Novo Nordisk reports pediatric obesity trial success amid market pressure
Novo Nordisk continues to expand its GLP-1 market presence, maintaining approximately a 43% global market share for obesity and diabetes treatments despite competition from Eli Lilly. The oral Wegovy pill remains a prima
GLP-1 drugs: clinical trends, safety, and market shifts
247 clusters · 895 sources · last updated
Latest: GLP-1 medications transform obesity treatment approach
Since mid-2026, the expansion of GLP-1 agents for obesity has been accompanied by intensified safety monitoring and evolving clinical data. Research suggests secondary benefits, including a 21% lower risk of fragility fr